CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.

autologous peripheral blood hematopoietic stem cell transplantation in preconditioning with busulfan and thiotepa. 5 She maintained complete remission for 3 years until the age of 50 years when head magnetic resonance imaging showed high-signal lesions on the T2-weighted FLAIR image again in the right occipital lobe. She had 5 courses of methotrexate CHOP chemotherapy combined with rituximab for half a year, leading to complete remission, and then underwent chimera antigen receptor T-cell therapy (tisagenlecleucel) based on the CD19 expression of lymphoma cells in the preserved vitrectomy cell block (Fig. 1C). One year later, she devel-oped impending branch retinal vein occlusion with retinal blot hemorrhages, venous dilation and tortuosity in the right eye, and showed spontaneous resolution in the 4 months. Otherwise, she had shown neither retinal manifestations nor recurrent vitreous opacity throughout the course. She was systemically well for 1.5 years and maintained the best-cor-rected visual acuity of 1.5 in both eyes until the latest follow-up at the age of 52 years.